Dimensional Fund Advisors LP Purchases 346,428 Shares of Agilent Technologies, Inc. $A

Key Points

• Dimensional Fund Advisors boosted its stake in Agilent by 23.7%, buying 346,428 shares to hold 1,808,380 shares total—about 0.64% of the company valued at roughly $232.0 million per its latest 13F filing.
• Analyst sentiment is positive with a consensus of "Moderate Buy" and an average target of $161.20; notable price-target moves include JPMorgan raising its target to $180 and Citigroup to $185 while UBS and Wells Fargo trimmed targets to $165.
• Agilent slightly missed quarterly estimates (EPS $1.36 vs. $1.37; revenue $1.80B vs. $1.81B), provided FY2026 guidance of 5.900–6.040 EPS, and announced a $0.255 quarterly dividend (annualized $1.02, ~0.9% yield; ex-dividend March 31).

Dimensional Fund Advisors LP raised its position in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 23.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,808,380 shares of the medical research company's stock after acquiring an additional 346,428 shares during the period. Dimensional Fund Advisors LP owned approximately 0.64% of Agilent Technologies worth $232,018,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Flynn Zito Capital Management LLC raised its stake in Agilent Technologies by 3.2% during the 3rd quarter. Flynn Zito Capital Management LLC now owns 2,257 shares of the medical research company's stock worth $290,000 after acquiring an additional 69 shares in the last quarter. Forum Financial Management LP grew its holdings in shares of Agilent Technologies by 2.5% during the third quarter. Forum Financial Management LP now owns 2,921 shares of the medical research company's stock worth $375,000 after purchasing an additional 70 shares during the last quarter. Wedmont Private Capital increased its position in shares of Agilent Technologies by 2.3% during the third quarter. Wedmont Private Capital now owns 3,630 shares of the medical research company's stock worth $503,000 after purchasing an additional 81 shares in the last quarter. waypoint wealth counsel increased its position in shares of Agilent Technologies by 4.3% during the third quarter. waypoint wealth counsel now owns 1,984 shares of the medical research company's stock worth $255,000 after purchasing an additional 82 shares in the last quarter. Finally, Cibc World Market Inc. lifted its holdings in shares of Agilent Technologies by 0.3% in the 3rd quarter. Cibc World Market Inc. now owns 29,076 shares of the medical research company's stock valued at $3,732,000 after purchasing an additional 85 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on A. JPMorgan Chase & Co. upped their target price on Agilent Technologies from $165.00 to $180.00 and gave the company an "overweight" rating in a research report on Tuesday, November 25th. Citigroup boosted their price objective on Agilent Technologies from $165.00 to $185.00 and gave the company a "buy" rating in a research note on Tuesday, November 25th. Wells Fargo & Company lowered their target price on shares of Agilent Technologies from $175.00 to $165.00 and set an "overweight" rating on the stock in a research report on Thursday, February 26th. UBS Group cut their target price on shares of Agilent Technologies from $180.00 to $165.00 and set a "buy" rating on the stock in a report on Thursday, February 26th. Finally, HSBC started coverage on shares of Agilent Technologies in a research report on Tuesday, January 20th. They issued a "buy" rating and a $180.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $161.20.

Agilent Technologies Stock Performance

NYSE:A opened at $115.11 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.07 and a quick ratio of 1.59. The firm has a market cap of $32.53 billion, a price-to-earnings ratio of 25.41, a price-to-earnings-growth ratio of 2.42 and a beta of 1.31. The firm's fifty day moving average price is $132.65 and its 200 day moving average price is $136.00. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $160.27.

Agilent Technologies (NYSE:A - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing analysts' consensus estimates of $1.37 by ($0.01). The firm had revenue of $1.80 billion for the quarter, compared to analysts' expectations of $1.81 billion. Agilent Technologies had a return on equity of 24.49% and a net margin of 18.26%.The firm's quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.31 EPS. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. On average, sell-side analysts expect that Agilent Technologies, Inc. will post 5.58 EPS for the current year.

Agilent Technologies Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 22nd. Shareholders of record on Tuesday, March 31st will be issued a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, March 31st. Agilent Technologies's payout ratio is currently 22.52%.

Agilent Technologies Company Profile

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.